Table 3.
Total and OOP costs for claims associated with outpatient services, inpatient services, chemotherapy, or radiotherapy across the time periods included in the study, stratified by cancer type
| Services | Time | ||||
|---|---|---|---|---|---|
| Preoperative period | Perioperative period | Adjuvant period | Surveillance period | ||
| Colon cancer (n = 7289) | |||||
| Total | n = 6066 | n = 7068 | n = 4130 | n = 6656 | |
| Total cost (US$) | 1341 (469–5234) | 41,729 (30,625–59,865) | 7119 (674–23,099) | 16,373 (3877–53,852) | |
| OOP (US$) | 339 (110–1015) | 2232 (999–3578) | 188 (60–600) | 891 (301–2094) | |
| OOP/total (%) | 21.0 (9.6–40.7) | 5.1 (2.1–9.2) | 4.6 (1.2–15.5) | 5.9 (2.0–16.3) | |
| Outpatient* | n = 6053 | n = 6927 | n = 4109 | n = 6647 | |
| Total cost (US$) | 1290 (463–4483) | 8211 (4827–13,655) | 5758 (646–20,108) | 13,241 (3670–43,124) | |
| OOP (US$) | 320 (105–905) | 795 (305–1630) | 180 (60–565) | 820 (291–1932) | |
| OOP/total (%) | 21.6 (10.0–41.7) | 10.3 (4.4–19.1) | 5.1 (1.4–15.9) | 6.6 (2.3–17.1) | |
| Inpatient* | n = 370 | n = 5784 | n = 166 | n = 601 | |
| Total cost (US$) | 19,050 (11,407–38,231) | 31,522 (22,794–46,549) | 18,636 (10,629–32,606) | 30,637 (16,148–53,431) | |
| OOP (US$) | 1338 (459–2480) | 1399 (586–2473) | 306 (171–905) | 807 (275–2078) | |
| OOP/total (%) | 6.6 (2.2–14.6) | 4.2 (1.7–8.3) | 1.8 (0.6–4.7) | 2.4 (0.8–6.7) | |
| Chemotherapy | n = 89 | n = 86 | n = 511 | n = 1042 | |
| Total cost (US$) | 14,923 (1238–40,166) | 1586 (353–8149) | 2499 (893–10,883) | 4508 (1471–24,737) | |
| OOP (US$) | 385 (58–1410) | 109 (34–669) | 129 (40–544) | 219 (61–828) | |
| OOP/total (%) | 3.0 (1.0–7.5) | 10.0 (2.5–20.0) | 7.1 (2.5–17.1) | 3.9 (1.4–10.9) | |
| Radiotherapy | n = 14 | n = 4 | n = 15 | n = 45 | |
| Total cost (US$) | 7116 (3050–14,927) | 1803 (235–8898) | 6265 (2925–12,605) | 6572 (1328–18,012) | |
| OOP (US$) | 156 (53–514) | 568 (308–1769) | 478 (75–1038) | 360 (90–1343) | |
| OOP/total (%) | 1.6 (1.0–5.5) | 7.1 (4.9–16.6) | 11.4 (1.4–20.0) | 4.0 (1.2–14.4) | |
| Rectal cancer (n = 3643) | |||||
| Total | n = 3198 | n = 3386 | n = 2058 | n = 3347 | |
| Total cost (US$) | 7379 (866–33,328) | 52,751 (36,672–76,256) | 13,382 (2863–27,852) | 32,542 (8435–70,708) | |
| OOP (US$) | 812 (195–2459) | 1955 (619–3421) | 231 (90–725) | 1131 (390–2465) | |
| OOP/total (%) | 12.5 (5.3–26.6) | 3.5 (1.0–7.3) | 2.9 (0.8–10.4) | 4.0 (1.6–10.7) | |
| Outpatient* | n = 3191 | n = 3327 | n = 2046 | n = 3333 | |
| Total cost (US$) | 6066 (859–29,606) | 13,331 (7144–25,550) | 9163 (1906–21,815) | 19,953 (6735–51,408) | |
| OOP (US$) | 711 (188–2215) | 837 (281–1799) | 205 (85–604) | 911 (339–2090) | |
| OOP/total (%) | 12.8 (5.4–27.1) | 6.8 (2.2–14.6) | 3.6 (1.1–11.4) | 4.9 (1.9–12.3) | |
| Inpatient* | n = 261 | n = 2349 | n = 162 | n = 551 | |
| Total cost (US$) | 19,426 (12,333–37,971) | 34,299 (24,937–50,987) | 19,869 (12,476–28,588) | 24,636 (16,417–43,646) | |
| OOP (US$) | 1284 (521–2361) | 1193 (467–2342) | 500 (250–1367) | 892 (297–1941) | |
| OOP/total (%) | 6.1 (2.0–13.7) | 3.4 (1.2–7.1) | 2.5 (1.1–8.2) | 2.6 (1.0–6.8) | |
| Chemotherapy | n = 169 | n = 135 | n = 312 | n = 585 | |
| Total cost (US$) | 360 (42–13,865) | 284 (60–2965) | 1884 (719–8260) | 3392 (1156–19,086) | |
| OOP (US$) | 36 (7–418) | 26 (6–115) | 152 (41–614) | 186 (45–708) | |
| OOP/total (%) | 6.5 (1.6–16.0) | 10.0 (2.8–20.0) | 9.4 (3.3–20.0) | 4.2 (1.5–10.8) | |
| Radiotherapy | n = 589 | n = 447 | n = 34 | n = 59 | |
| Total cost (US$) | 7666 (3327–16,205) | 5626 (2364–15,078) | 8913 (4111–20,566) | 8936 (2943–23,145) | |
| OOP (US$) | 380 (144–949) | 318 (106–843) | 443 (100–1211) | 468 (158–1060) | |
| OOP/total (%) | 6.3 (2.0–13.0) | 4.4 (1.7–10.2) | 4.3 (1.1–10.0) | 5.2 (1.4–9.9) | |
Costs calculated only for patients who had at least one claim associated with out-of-pocket costs in the period of interest (n)
OOP out-of-pocket
*Costs associated with inpatient or outpatient services also include costs associated with chemotherapy and/or radiotherapy